Greenwich LifeSciences, Inc. GLSI 深 滬
等待開盤 08-22 09:30:00 美东时间
11.85
-0.090
-0.75%
華盛通- 最 高12.3499
- 今 開11.94
- 成交量 3.90万股
- 最 低 11.79
- 昨 收 11.94
- 總市值 1.58亿
- 52周最高 16.50
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 8.06
- 委 比 34.49%
- 總股本 1336.83万
- 歷史最高 158.07
- 量 比 0.78
- 振 幅 4.69%
- 歷史最低 3.262
- 每 手 1
- 風險率 2.78%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences
Greenwich LifeSciences announced that Noble Capital Markets has initiated equity research coverage on the company. The company is focused on its Phase III FLAMINGO-01 trial evaluating GLSI-100, an immunotherapy for preventing breast cancer recurrences in HER2 positive patients. The trial aims to enroll up to 750 patients globally and is led by Baylor College of Medicine. For more details, visit the company's website or clinicaltrials.gov.
08-20 13:25
Greenwich LifeSciences Cuts Costs by Bringing Breast Cancer Trial Management In-House
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent
08-19 18:04
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team
Greenwich LifeSciences announced plans to build its internal clinical trial management team to reduce reliance on external CROs, lowering costs and improving efficiency for its Phase III FLAMINGO-01 trial evaluating GLSI-100 for breast cancer prevention. The company is hiring dedicated staff to manage the trial, which includes up to 150 global sites and approximately 750 patients, aiming to enhance data quality and flexibility for future trials.
08-19 10:00
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences expands its FLAMINGO-01 clinical trial into Romania, adding sites to its existing 150 global locations. The trial evaluates GLSI-100, an immunotherapy for preventing breast cancer recurrence. Romania, with 12,861 new breast cancer cases in 2022, is the first European country added. Collaborating with Dr. Nicoleta Antone, a leading breast cancer expert, the company aims to enroll Romanian patients soon. FLAMINGO-01 is a Phas...
08-13 10:00
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events
Greenwich LifeSciences, a clinical-stage biopharmaceutical company, focuses on developing GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company recently provided updates on CEO interviews and corporate events, including videos of interviews available on their website. Greenwich LifeSciences is currently conducting the FLAMINGO-01 Phase III clinical trial for GLSI-100 in HER2-positive breast cancer patients. The trial aims t...
08-11 10:00
Greenwich LifeSciences Q1 EPS $(0.25) Down From $(0.19) YoY
Greenwich LifeSciences (NASDAQ:GLSI) reported quarterly losses of $(0.25) per share. This is a 31.58 percent decrease over losses of $(0.19) per share from the same period last year.
05-21 05:58
美股大行评级 | 潜在涨幅3020.12%！Ascendiant Capital上调Plus Therapeutics目标价至20美元，维持"买入"评级
每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。
04-22 08:41
Greenwich LifeSciences Announced An Update On FLAMINGO-01 Open Label Safety Data
FLAMINGO-01 Data Safety Monitoring Board (DSMB)The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to continue the study as is without modification. No serious adverse events related
03-17 18:47
美股大行评级 | 潜在涨幅119%！Compass医疗获杰富瑞升目标价至8美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1096354625327304705.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Jones Trading：上调In8bio(INAB)评级至"买入"，目标价1.2美元</p> <p>• 丰业银行：维持INmune Bio(INMB)"跑赢大市"评级，目标价从22美元升至23美元</p> <p>•
02-12 09:54
Greenwich LifeSciences Reports Initiation Of New Clinical Sites In US
Both Harvard University and Johns Hopkins University sites were recently added as participating sites in FLAMINGO-01 in the US and both principal investigators, Laura Spring and Cesar Santa-Maria have joined the Steering
01-23 19:09
